Esclerodermia

Its prognosis depends on the involvement of important organs such as the lungs, kidneys and heart, which is why it is still a disease with a high morbidity and mortality. Progress in the study of the pathogenesis and the identification of biomarkers has allowed for the emergence of new therapies with promising results, though clinical trials to evidence their efficacy is required.